Caplin Point Laboratories Stock Screener | Share Price & Fundamental Analysis
CAPLIPOINT
Pharmaceuticals
Screen Caplin Point Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1845.30
▼
-3.50 (-0.19%)
Share Price BSE
₹1845.95
▼
-4.10 (-0.22%)
Market Cap
₹13,888.86 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
4.43
EPS (TTM)
₹70.57
Dividend Yield
0.33%
Debt to Equity
-
52W High
₹2583.25
52W Low
₹1713.80
Operating Margin
33.00%
Profit Margin
27.46%
Revenue (TTM)
₹528.00
EBITDA
₹194.00
Net Income
₹145.00
Total Assets
₹3,208.00
Total Equity
₹2,886.00
Caplin Point Laboratories Share Price History - Stock Screener Chart
Screen CAPLIPOINT historical share price movements with interactive charts. Analyze price trends and patterns.
Caplin Point Laboratories Company Profile - Fundamental Screener
Screen Caplin Point Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CAPLIPOINT shares.
Caplin Point Laboratories Limited is an Indian pharmaceutical company founded in 1990. It develops, produces, and markets generic formulations and branded products globally. The company has manufacturing facilities in India and serves markets in Latin America, Africa, the USA, and the European Union. Caplin Point specializes in various pharmaceutical formulations, including injectables, tablets, capsules, and syrups. The company has expanded through acquisitions, partnerships, and investments in subsidiaries. It has a strong presence in emerging markets and has entered regulated markets like the USA. Caplin Point has invested in research and development, including API development and clinical research. The company has also ventured into e-commerce and has been expanding its product portfolio and manufacturing capabilities.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
C C Paarthipan
ISIN
INE475E01026
Website
https://www.caplinpoint.net
Caplin Point Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen CAPLIPOINT balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 3,208 | 2,698 | 2,191 | 1,736 | 1,364 | 1,126 | 743 | 501 | 358 | 267 |
| Current Assets | 2,134 | 1,893 | 1,552 | 1,298 | 1,015 | 823 | 494 | 304 | 179 | 119 |
| Fixed Assets | 546 | 453 | 280 | 287 | 305 | 273 | 227 | 170 | 152 | 144 |
| Liabilities | ||||||||||
| Total Liabilities | 3,208 | 2,698 | 2,191 | 1,736 | 1,364 | 1,126 | 743 | 501 | 358 | 267 |
| Current Liabilities | 16 | 20 | 16 | 19 | 17 | 25 | 23 | 28 | 20 | 14 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 2,886 | 2,347 | 1,907 | 1,510 | 1,203 | 957 | 633 | 364 | 225 | 128 |
| Share Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves & Surplus | 2,619 | 2,084 | 1,649 | 1,252 | 954 | 716 | 514 | 349 | 210 | 113 |
Screen CAPLIPOINT income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 528 | 533 | 564 | 471 | 478 | 504 | 524 | 401 | 407 | 431 | 453 | 351 | 360 | 376 | 386 |
| Expenses | 334 | 333 | 345 | 308 | 307 | 318 | 331 | 265 | 269 | 273 | 293 | 239 | 244 | 254 | 263 |
| EBITDA | 194 | 201 | 220 | 163 | 170 | 185 | 194 | 135 | 139 | 158 | 160 | 111 | 116 | 122 | 124 |
| Operating Profit % | 33.00% | 35.00% | 35.00% | 32.00% | 33.00% | 34.00% | 33.00% | 32.00% | 32.00% | 34.00% | 33.00% | 29.00% | 30.00% | 29.00% | 29.00% |
| Depreciation | 17 | 16 | 18 | 16 | 16 | 17 | 16 | 11 | 11 | 12 | 14 | 11 | 11 | 12 | 11 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 177 | 185 | 201 | 146 | 154 | 169 | 177 | 124 | 127 | 146 | 145 | 100 | 105 | 110 | 112 |
| Tax | 31 | 34 | 41 | 25 | 30 | 38 | 37 | 23 | 23 | 30 | 26 | 19 | 19 | 18 | 14 |
| Net Profit | 145 | 151 | 160 | 121 | 125 | 131 | 140 | 101 | 104 | 116 | 120 | 81 | 86 | 92 | 97 |
| EPS | 18.75 | 20.10 | 20.32 | 16.01 | 16.32 | 17.22 | 18.28 | 13.45 | 13.62 | 15.13 | 15.44 | 10.43 | 11.21 | 12.09 | 12.86 |
Caplin Point Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen CAPLIPOINT cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 432 | 318 | 271 | 337 | 269 | 45 | 83 | 67 | 68 | 42 |
| Investing Activities | -333 | -319 | -216 | -377 | -30 | -54 | -100 | -69 | -36 | -6 |
| Financing Activities | -38 | -38 | -28 | -41 | -24 | 80 | 90 | -12 | -7 | -14 |
| Net Cash Flow | 61 | -39 | 27 | -81 | 215 | 70 | 74 | -14 | 25 | 23 |
Screen CAPLIPOINT shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 70.56% | 70.56% | 70.57% | 70.62% | 70.56% | 70.56% | 70.56% | 70.66% |
| FII Holding | 5.73% | 6.17% | 6.51% | 3.34% | 3.37% | 3.70% | 4.86% | 0.00% |
| DII Holding | 2.01% | 2.22% | 2.10% | 1.09% | 1.49% | 1.84% | 2.11% | 0.65% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 15.11% | 14.32% | 14.20% | 17.59% | 17.50% | 17.12% | 15.77% | 18.73% |
| Other Holding | 6.59% | 6.73% | 6.61% | 7.36% | 7.08% | 6.78% | 6.70% | 9.96% |
| Shareholder Count | 96,387 | 94,169 | 93,753 | 81,409 | 80,411 | 96,123 | 92,702 | 82,146 |
Caplin Point Laboratories Dividend Screener - Share Yield Analysis
Screen CAPLIPOINT dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹6.00 | 0.33% |
| 2024-March | ₹5.00 | 0.25% |
| 2023-March | ₹4.50 | 0.34% |
| 2022-March | ₹4.00 | 0.68% |
| 2021-March | ₹3.00 | 0.44% |
| 2020-March | ₹2.50 | 0.62% |
| 2019-March | ₹2.20 | 0.78% |
| 2018-March | ₹2.00 | 0.50% |
| 2017-March | ₹1.50 | 0.26% |
Caplin Point Laboratories Index Membership - Market Screener Classification
Screen CAPLIPOINT by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Caplin Point Laboratories Market Events Screener - Corporate Actions
Screen CAPLIPOINT market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 2.50 /share | 25.81% | ||
| Dividend | ₹ 1.50 /share | 0.39% | ||
| Annual General Meeting | NA | 21.42% | ||
| Dividend | ₹ 2.00 /share | -11.83% | ||
| Dividend | ₹ 3.00 /share | 15.96% | ||
| Dividend | ₹ 2.50 /share | 5.22% | ||
| Annual General Meeting | NA | 23.99% | ||
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | -0.93% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -7.48% |
| 2025-05-30 | 2025-05-30 | Dividend | ₹ 3.00 /share | 7.27% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 8.78% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 7.19% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 12.11% |
| 2024-05-31 | 2024-05-31 | Dividend | ₹ 2.50 /share | -4.49% |
| 2023-06-09 | 2023-06-09 | Dividend | ₹ 2.00 /share | 9.81% |
Caplin Point Laboratories Competitors Screener - Peer Comparison
Screen CAPLIPOINT competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 410,574 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 168,891 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,088 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,432 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,487 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 95,476 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 91,723 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,703 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 68,331 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,007 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Caplin Point Laboratories Company Announcements - News Screener
Screen CAPLIPOINT latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Closure of Trading Window | View |
| 2026-01-06 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-12-12 | Completion Of Inspection By INVIMA-Colombia At The Puducherry Injectables Facility Of The Company | View |
| 2025-12-09 | Press Release On USFDA Approval | View |
| 2025-12-08 | Intimation Of Press Release | View |
| 2025-11-14 | Acquisition Of Land By Subsidiary | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-05 | Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September 2025 | View |
| 2025-11-05 | Board Meeting Outcome for Outcome Of The Board Meeting | View |
| 2025-10-29 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half-Year Ended September 30 2025 | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-29 | Board Meeting Intimation for Considering And Approving Inter-Alia The Unaudited Financial Results Of The Company For The Quarter And Half-Year Ended September 30 2025 | View |
| 2025-10-23 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-04 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-29 | Closure of Trading Window | View |
| 2025-09-23 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-22 | Announcement under Regulation 30 (LODR)-Change in Management | View |